These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25055724)

  • 1. Clinical significance of interleukin-22 in multiple myeloma.
    Tsirakis G; Pappa CA; Kolovou A; Kokonozaki M; Neonakis I; Alexandrakis MG
    Hematology; 2015 Apr; 20(3):143-7. PubMed ID: 25055724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
    Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
    J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
    Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
    Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
    Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG
    Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
    Alexandrakis MG; Pappa CA; Kokonozaki M; Boula A; Vyzoukaki R; Staphylaki D; Papadopoulou A; Androulakis N; Tsirakis G; Sfiridaki A
    Med Oncol; 2015 Mar; 32(3):42. PubMed ID: 25631632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietic cytokines and platelet count in multiple myeloma.
    Ozkurt ZN; Yağci M; Sucak GT; Kirazli S; Haznedar R
    Platelets; 2010; 21(1):33-6. PubMed ID: 19891528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.
    Pappa C; Miyakis S; Tsirakis G; Sfiridaki A; Alegakis A; Kafousi M; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2007 Feb; 37(2):171-5. PubMed ID: 17446083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum level of IL-17 in patients with multiple myeloma and its clinical significance].
    Zhang XL; Zhang WH; Fan XH; Wei F; Zhang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):930-2. PubMed ID: 22931657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.